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Abstract
Background: Though TRAIL has been hailed as a promising drug for tumour treatment, it has been observed that
many tumour cells have developed escape mechanisms against TRAIL-induced apoptosis. As a receptor of LPS, TLR
4, which is expressed on a variety of cancer cells, can be associated with TRAIL-resistance of tumour cells and
tumour progression as well as with the generation of an anti-tumour immune response.
Methods: In this study, the sensitivity to TRAIL-induced apoptosis as well as the influence of LPS-co-stimulation on
the cell viability of the pancreatic cancer cell lines PANC-1, BxPC-3 and COLO 357 was examined by FACS analyses
and a cell viability assay. Subsequently, the expression of TRAIL-receptors was detected via FACS analyses. Levels of
osteoprotegerin (OPG) were also determined using an enzyme-linked immunosorbent assay.
Results: PANC-1 cells were shown to be resistant to TRAIL-induced apoptosis. This was accompanied by
significantly increased osteoprotegerin levels and a significantly decreased expression of DR4.
In contrast, TRAIL significantly induced apoptosis in COLO 357 cells and to a lesser degree in BxPC-3 cells.
Co-stimulation of COLO 357 as well as BxPC-3 cells combining TRAIL and LPS resulted in a significant
decrease in TRAIL-induced apoptosis. In COLO 357 cells TRAIL-stimulation decreased the levels of OPG thereby
not altering the expression of the TRAIL-receptors 1–4 resulting in a high susceptibility to TRAIL-induced
apoptosis. Co-stimulation with LPS and TRAIL completely reversed the effect of TRAIL on OPG levels reaching
a 2-fold increase beyond the level of non-stimulated cells resulting in a lower susceptibility to apoptosis.
In BxPC-3, TRAIL stimulation decreased the expression of DR4 and significantly increased the decoy receptors
TRAIL-R3 and TRAIL-R4 leading to a decrease in TRAIL-induced apoptosis. OPG levels remained unchanged.
Co-stimulation with TRAIL and LPS further enhanced the changes in TRAIL-receptor-expression promoting
apoptosis resistance.
Conclusions: Here it has been shown that TRAIL-resistance in pancreatic cancer cells can be mediated by the
inflammatory molecule LPS as well as by different expression patterns of functional and non-functional TRAIL-
receptors.
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Background
Pancreatic cancer remains a devastating disease which
displays resistance to even the most aggressive treatment re-
gime [1]. There is increasing evidence that the development
and progression of exocrine pancreatic cancer can be pro-
moted by chronic inflammation [2–4]. This connection of
inflammation with tumour progression can be mediated by
components of the bacterial cell wall like lipopolysaccharide
(LPS) from gram-negative bacteria [5]. LPS interacts with
immune cells of the tumour microenvironment which, in
turn, is especially important in tumour development and
progression [2, 6]. Additionally, LPS can directly interact
with pancreatic cancer cells increasing the invasive ability of
these cells [5]. LPS is recognized by the Toll-like receptor
(TLR) 4. TLRs are a family of pattern recognition receptors
exerting an important role in host defence against infections
[7]. Apart from the expression of TLR4 by cells of the
immune system, TLRs have been linked to several cancers
including pancreatic cancer [5, 8–14]. In these tumours,
LPS can lead to activation of NFkB thus promoting cancer
progression and chemoresistance [13].
TNF-related apoptosis inducing ligand (TRAIL) is in-
volved in tumour surveillance. It induces apoptosis upon
binding to its receptors death receptor (DR) 4 (TRAIL-
receptor 1) and DR5 (TRAIL-receptor 2). Additionally,
there are three more TRAIL receptors lacking a
functionally active death domain: TRAIL-receptor
(TRAIL-R) 3 (decoy receptor 1 or DcR1), TRAIL-R 4
(decoy receptor 2 or DcR2) and the soluble receptor os-
teoprotegerin (OPG). Thus, they are unable to transmit
apoptosis-inducing signals [15]. Several factors deter-
mine whether a cell becomes apoptotic following
TRAIL-binding: Firstly, many cells express these decoy-
receptors inhibiting TRAIL at the membrane level:
TRAIL-R3 (DcR1) competes for TRAIL binding, seques-
tering TRAIL in lipid rafts. TRAIL-R4 (DcR2) inhibits
activation of caspase 8 through the formation of hetero-
meric complexes [16]. Secondly, the cell cycle progres-
sion can change the balance of pro- and anti-apoptotic
proteins. These proteins collectively help to regulate the
signal generated by binding of TRAIL to DR4 or DR5.
Thus, a preponderance of anti-apoptotic proteins may
result in TRAIL-resistance [17]. Especially members of the
Bcl-2 family, cFLIP and IAPs (inhibitor of apoptosis pro-
teins) contribute to TRAIL receptor-signal-transduction
pathways leading to TRAIL resistance [17–19].
Despite TRAIL-R1/2 – expression, most pancreatic
cancer cells show resistance to TRAIL-induced apoptosis
[20–23] mediated by a high activation level of NF-
kappaB [24] which enhances the expression of inhibitors
of apoptosis like XIAP and FLIP [20–23].
In human colon cancer cell lines, it has been
detected by Tang et al. [25] that LPS binding to TLR-
4 did not affect the expression of TLR4 nor
proliferation of respective cell lines. However, LPS ac-
tivated NFkB thereby inducing resistance to TRAIL-
induced apoptosis [25].
For human lung cancer cell lines, it has been shown
that TLR 4 ligation by LPS led to production of anti-
inflammatory cytokines as well as resistance of human
lung cancer cells to TNFa- and TRAIL-mediated apop-
tosis. Furthermore, binding of LPS to its receptor TLR4
can activate NFkB thereby promoting resistance to
TRAIL – induced apoptosis [26].
In the present study, the effects of LPS stimulation on
TRAIL-induced apoptosis in several pancreatic cancer
cell lines were examined.
Methods
Cell lines
The human pancreatic cancer cell lines PANC-1 and
BxPC-3 were obtained from the ATCC (American Type
Culture Collection, Manassas, VA, USA). The cell line
COLO 357 was obtained from ECACC (European Col-
lection of Authenticated Cell Cultures, London, UK).
Cells were maintained in RPMI 1640 (Gibco cell culture,
Karlsruhe, Germany) supplemented with 10% heat-
inactivated fetal bovine serum (FCS) (PAA, Pasching,
Austria) and 1% penicilline/streptomycine (Gibco cell
culture) at 37 °C in a 5% CO2 atmosphere at 85%
humidity.
LPS and TRAIL stimulation
Human recombinant TRAIL (purity 95%, endotoxin
level < 1.0 EU per 1 g protein) was purchased from Bio-
mol (Hamburg, Germany) and dissolved in RPMI
medium. Lipopolysaccharide (E. coli) was purchased
from Sigma Aldrich (Munich, Germany). Cells were
seeded in six well plates. After 12 h, respective amounts
of TRAIL (100 ng/ml or 300 ng/ml) and/or LPS (1 μg/
ml) were added and cells were stimulated for 24 h.
Detection of apoptotic cells
Apoptotic cell death was assessed using an Annexin V
Apoptosis Detection Kit (BD Bioscience, Heidelberg,
Germany) according to manufacturer’s instructions.
Annexin V-positive cells were detected by flow cytometry
(FACS Canto, Becton Dickinson, Heidelberg, Germany).
To confirm the results, a propidium iodide cell cycle
analysis was performed. For this assay, cells were har-
vested, stored on ice and washed three times with 2%
FCS in PBS. A total of 105 cells were fixed in 70% etha-
nol and incubated with 0.025 M sodium citrate and
0.067 M disodium phosphate. The pellets were washed
with PBS plus 5% FCS, resuspended in 30 μl RNase
(1 mg/mL; Qiagen, Hilden, Germany) and stained with
25 μg/mL propidium iodide (Sigma Aldrich). Apoptosis
was measured by flow cytometry (FACS Canto, Becton
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Dickinson, Heidelberg, Germany) employing a standard
protocol as described before [27]. In detail, cells were
stored on ice and washed 3 times with 2% fetal calf
serum (Biochrom) in PBS. A total of 105 cells were fixed
in 70% ethanol and incubated with 0.025 M sodium cit-
rate and 0.067 M disodium phosphate at pH 7.8 at room
temperature. The pellets were washed with PBS plus 5%
FCS, resuspended in 30 μL RNase (1 mg/mL; Qiagen,
Hilden, Germany) and stained with 25 g/mL propidium
iodide (Sigma Aldrich, Munich, Germany). Apoptosis
was measured by FlowCytometry (FACS Canto, Becton
Dickinson). Debris were gated out in the FSC versus
SSC plot. Singlets were manually gated in the FL2A
versus FL2W plot. The hypodiploid DNA peaks in
singlevariable DNA histograms were identified. Data
were analysed using BD CellQuest Pro.
Cell viability assay
A Cell Titer Blue Assay (Promega, Mannheim,
Germany) was performed according to the manufac-
turer’s instructions. In brief, Cell Titer Blue substrates
were added and plates were incubated for 4 h at 37 °C.
Subsequently, fluorescence (excitation at 544 nm and
emission at 590 nm) was measured on a plate reader.
Triplicates were run for each measurement and means
were calculated. Controls without cells were run in
parallel.
FACS analyses of TRAIL-receptors
After stimulation cells were harvested using accutase
(Sigma Aldrich) and washed with PBS. After blocking
with FcBlock (BD Bioscience, Heidelberg, Germany) cells
were labelled with appropriate antibodies according to
the manufacturer’s instructions. Purified mouse mono-
clonal antibodies of anti-human DR4, anti-human DR5,
anti-human DcR1 and anti-human DcR2 as well as
appropriate secondary antibodies and isotype controls
were purchased from Pierce (ThermoFisher Scientific,
Schwerte, Germany). FACS analyses were performed
using the above flow cytometer. FACS data were ana-
lysed using WinMDI.
Osteoprotegerin ELISA
Levels of osteoprotegerin within the cell culture super-
natants were detected using an osteoprotegerin – ELISA
(Bender MedSystems, Vienna, Austria) according to the
manufacturer’s recommondations.
Real time quantitative PCR
After stimulation of respective cell lines, cells were har-
vested and washed with PBS. RNA was extracted using
an RNeasy kit (Qiagen, Hilden, Germany) and quantified
by spectrophotometry. Subsequently, cDNA was pre-
pared using an RT2 PCR Array first strand kit (Qiagen).
Respective primers (i.e. TLR4, GAPDH and becta-actin)
(Qiagen) were used according to the manufacturer’s
recommondations. Realtime PCR amplification was
conducted using an ABI Prism 7000 (ThermoFisher
Scientific). Data were analysed using a SuperArray PCR
Data analyses software using the comparative threshold
method. Data were normalized to the house keeping
genes GAPDH and beta-actin.
Statistics
Results were statistically analysed using the program
Graph Pad Prism for Macintosh. The Mann Whitney U
test was employed to compare means of values of exper-
iments in order to test two independent samples. An
ANOVA test was employed to compare more than two
independent samples. A p-value below 0.05 was consid-
ered to be statistically significant. All data are expressed
as mean standard error of the mean.
Results
TRAIL – stimulation decreased viability of COLO 357 and
BxPC-3 whereas viability of PANC-1 cells remained almost
unchanged
To determine the impact of TRAIL-stimulation on cell
viability, cell cultures of PANC-1, BxPC-3 and COLO
357 were TRAIL-stimulated for 24 h and cell viability
was determined by a CellTiter Blue Assay. In COLO 357
cells, the mean fluorescence intensity (MFI) ratio was
43256 ± 5347 without stimulation. TRAIL-stimulation
decreased the MFI ratio in a dose-dependent manner
(10 ng/ml: 33701 ± 3486 (p = 0.17, n = 5); 100 ng/ml
11213 ± 2784 (p = 0.0007 when compared to non-
stimulated control; p = 0.001 when compared to 10 ng/
ml TRAIL; n = 5); 300 ng/ml 7276 ± 589 (p = 0.0002
when compared to non-stimulated control, p = 0.0001
when compared to 10 ng/ml TRAIL, p = 0.01 when com-
pared to 100 ng/ml TRAIL; n = 5; Fig. 1a).
In BxPC-3 cell cultures, stimulation with 10 ng/ml
TRAIL did not significantly alter the cell viability (MFI
ratio 29644 ± 1356 versus 31537 ± 479, p = 0.22; n = 5;
Fig. 1a). However, higher concentrations of TRAIL led
to decreased amounts of viable cells (100 ng/ml TRAIL:
18292 ± 1189 (p = 0.0002 when compared to non-
stimulated control, p = 0.0001 when compared to 10 ng/
ml TRAIL); 300 ng/ml TRAIL: 11853 ± 589 (p = 0.0001
when compared to non-stimulated control, p = 0.0001
when compared to 10 ng/ml TRAIL, p = 0.0012 when
compared to 100 ng/ml TRAIL); n = 5; Fig. 1a). The pan-
creatic cancer cell line PANC-1 was the most resistant
pancreatic cancer cell line of those tested. TRAIL-
stimulation with at least 300 ng/ml did significantly re-
duce cell viability but only to a minor degree (without
stimulation: 59872 ± 548; 10 ng/ml TRAIL: 58714 ±
1125; 100 ng/ml TRAIL: 58562 ± 1593; 300 ng/ml
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TRAIL: 49993 ± 783 (p = 0.001 when compared to
300 ng/ml TRAIL; n = 5) (Fig. 1a).
TRAIL-stimulation induced apoptosis in COLO 357 and, to
a lesser degree, in BxPC-3 cells, whereas PANC-1 cells
were TRAIL-resistant
The amounts of apoptotic cells induced by TRAIL-
stimulation were detected by an Annexin V assay.
Whereas the fraction of apoptotic cells was only 5.1 ±
0.94% in non-stimulated cell cultures of COLO 357,
TRAIL-stimulation for 24 h led to a dose-dependent in-
duction of apoptosis (25.7 ± 2.89% in COLO357 cell cul-
tures stimulated with 100 ng/ml TRAIL (p = 0.0001) and
52.8 ± 5.39% following stimulation with 300 ng/ml
TRAIL (p < 0.0001 when compared to non-stimulated
control, p = 0.0022 when compared to 100 ng/ml TRAIL;
n = 5, Fig. 1b).
When examining cell cultures of BxPC-3, TRAIL-
stimulation with 100 ng/ml significantly enhanced the
fraction of apoptotic cells (4.2 ± 0.78% versus 15.43 ±
4.58%, p = 0.042; n = 5; Fig. 1b). This effect was further
increased when stimulating with 300 ng/ml TRAIL
reaching 31.32 ± 3.27% apoptotic cells (p < 0.0001 when
compared to non-stimulated cells, p = 0.0224 when
compared to 100 ng/ml TRAIL, n = 5).
In marked contrast, in PANC-1 cell cultures the frac-
tion of apoptotic cells remained below 5% following
TRAIL stimulation indicating that PANC-1 is a cell line
resistant to TRAIL-induced apoptosis.
These results indicate that COLO 357 displays a high
susceptibility towards TRAIL-induced apoptosis whereas
PANC-1 cell cultures are TRAIL-resistant. Cultures of
BxPC-3 cells display intermediate sensibilities against
TRAIL-induced apoptosis.
These data were confirmed using a propidium iodide
cell cycle assay (data not shown).
LPS stimulation inhibited TRAIL-induced apoptosis
To assess an effect of LPS stimulation on apoptosis
induction by TRAIL, respective cell cultures were
Fig. 1 LPS-stimulation promoted resistance to TRAIL-induced apoptosis. a Cells cultures of COLO357, BxPC-3 and PANC-1 were stimulated with
TRAIL for 24 h and cell viability was determined using a Cell titer blue assay. Mean fluorescence intensities following TRAIL-stimulation are shown.
TRAIL – stimulation decreased viability of COLO 357 and BxPC-3 whereas viability of PANC-1 cells remained almost unchanged. N= 5/group. b Cell cultures
of COLO357, BxPC-3 and PANC-1 were TRAIL-stimulated for 24 h and the fraction of apoptotic cells was determined via FACS analyses
employing a Annexin V assay. TRAIL-stimulation induced apoptosis in COLO 357 and, to a lesser degree, in BxPC-3 cells, whereas PANC-1
cells were TRAIL-resistant. N = 5/group. c Cell cultures of COLO357, BxPC-3 and PANC-1 were stimulated with 300 ng/ml TRAIL, 1 μg/ml LPS
and 300 ng/ml TRAIL + 1 μg/ml LPS for 24 h. Non-stimulated cell cultures served for controls. Thereafter, fractions of apoptotic cells were
determined. Co-stimulation with TRAIL and LPS significantly decreased the number of TRAIL-induced apoptotic cells in COLO357 and
BxPC-3. N = 5/group. d Representative histograms of FACS analyses employing the Annexin V assay of COLO357 and BxPC-3 are shown.
Means and standard errors of the mean are shown. *) p < 0.05; **) p < 0.01; ***) p < 0.001
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stimulated with 300 ng/ml TRAIL, 1 μg/ml LPS and
300 ng/ml TRAIL + 1 μg/ml LPS. Thereafter, fractions of
apoptotic cells were determined. In the TRAIL-resistant
pancreatic cancer cell line PANC-1, co-stimulation with
LPS and TRAIL did not lead to any significant alter-
ations in the fraction of apoptotic cells. Thus, there were
3.28 ± 1.0% apoptotic cells without stimulation. LPS-
stimulation revealed 3.8 ± 0.9% apoptotic cells. Stimula-
tion with 300 ng/ml TRAIL and LPS resulted in 3.5 ±
1.3% apoptotic cells.
In non-stimulated COLO 357 cells, there were 5.1 ±
0.94% cells apoptotic. TRAIL-stimulation led to 52.8 ±
5.39% apoptotic cells (p < 0.0001, n = 5) whereas LPS-
stimulation revealed 6.1% ± 1.90% apoptotic cells (n = 5,
p = 0.66 when compared to non-stimulated cells, Fig. 1c).
Co-stimulation with TRAIL and LPS partially reversed
the effect of TRAIL on apoptosis-induction revealing
26.4 ± 3.21% apoptotic cells (n = 5, p = 0.003 when com-
pared to TRAIL-stimulated cell cultures; Fig. 1c).
In BxPC-3 cultures, there were 4.2 ± 0.78% apoptotic
cells. TRAIL treatment led to 31.32 ± 3.27% apoptotic
cells (n = 5, p < 0.0001). Co-stimulation with TRAIL and
LPS significantly decreased the number of apoptotic cells
reaching 18.3 ± 2.84% (n = 5, p = 0.0169 when compared
to TRAIL-stimulated cell cultures) whereas stimulation
with LPS alone did not have an impact on apoptosis
(3.9 ± 1.3%, Fig. 1c).
In PANC-1 cells TRAIL-stimulation decreased the expres-
sion of DR4, DR5 and DcR2 as well as increasing the ex-
pression of osteoprotegerin (OPG)
As shown by FACS analyses, PANC-1 cells expressed
the TRAIL-receptors DR4, DR5, DcR1 and DcR2
(Fig. 2a,b). Additionally, significant amounts of OPG
were detected in the supernatants of PANC-1 cell cul-
tures (Fig. 2c). Following TRAIL-stimulation, the expres-
sion of the death receptors DR4 and DR5 by PANC-1
cells was decreased. For DR4 the mean fluorescence in-
tensity (MFI) was 1397 ± 145.8 for non-stimulated cell
cultures, whereas TRAIL-stimulated cell cultures
showed a mean fluorescence intensity of 436.8 ± 76.0 (p
= 0.0001, n = 6/group). For DR5 the mean fluorescence
intensity was 1025 ± 77.8 in non-stimulated cells,
whereas TRAIL-stimulation led to a mean fluorescence
intensity of 663.6 ± 72.5 (p = 0.005, n ≥ 7/group). The
expression of DcR1 remained unchanged following
Fig. 2 TRAIL-stimulation decreased the expression of DR4, DR5 and DcR2 as well as increasing the expression of osteoprotegerin (OPG) in PANC-1 cells.
Cultures of PANC-1 cells were stimulated with 300 ng/ml TRAIL for 24 h. The expression of the TRAIL-receptors 1–4 was detected by FACS analyses.
The concentrations of OPG within the supernatants were determined by ELISA. a The expression of respective TRAIL-receptors is expressed as mean
fluorescence intensity. TRAIL-stimulation of PANC-1 cells led to significantly decreased expressions of DR4 (TRAIL receptor 1), DR5 (TRAIL receptor 2)
and DcR2 (TRAIL receptor 4) whereas the expression of DcR1 (TRAIL receptor 3) remained unaltered. N≥ 6/group. b Representative histograms show
the expression of TRAIL-receptors 1 – 4 in TRAIL-stimulated PANC-1 cells and unstimulated controls. c The concentration of OPG within the cell culture
supernatant increased following TRAIL-stimulation. N = 7/group. Means and standard errors of the mean are shown. *) p < 0.05; **) p < 0.01;
***) p < 0.001
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TRAIL-stimulation (MFI 361.4 ± 108.4, n = 5 versus
477.0 ± 77.5, n = 7, p = 0.39). In contrast, the expression
of DcR2 significantly decreased following TRAIL-
treatment. The MFI of DcR2 was 537.5 ± 28.9 in non-
stimulated cell cultures but decreased to 396.8 ± 25.3
following TRAIL-stimulation (p = 0.009; Fig. 2a).
The levels of OPG within the cell culture supernatants
of PANC-1 cell cultures were 29.71 ± 4.1 pg/ml in non-
stimulated controls. TRAIL-stimulation increased the
concentration of OPG within the supernatants revealing
45.29 ± 8.5 (n = 7, p = 0.1).
LPS stimulation significantly affected the impact of TRAIL
on TRAIL-receptor-expression
As shown by FACS analyses, COLO 357 cells expressed
the TRAIL-receptors 1–4. Neither TRAIL-stimulation
alone nor LPS-stimulation alone significantly altered the
expression of TRAIL-receptors by COLO 357 cells
(Fig. 3a). In contrast, TRAIL-stimulation significantly de-
creased the levels of OPG: Whereas the concentration of
OPG in the cell culture supernatants was 18.67 ± 3.8 pg/
ml in non-simulated cell cultures, TRAIL stimulation
decreased the OPG secretion reaching 10.60 ± 1.5 pg/ml
(p = 0.06). This effect was significantly reversed by co-
stimulation with LPS: Co-stimulation with TRAIL and
LPS increased the OPG concentration reaching 37.83 ±
6.4 pg/ml (p = 0.0044 when compared to TRAIL-
stimulated COLO 357 cultures, n = 6/group, Fig. 3b).
In contrast, in BxPC-3 cells neither stimulation with
TRAIL alone nor co-stimulation with TRAIL and LPS
significantly altered the levels of OPG: The concentra-
tion of OPG within supernatants of BxPC-3 cultures was
11.0 ± 1.1 pg/ml without stimulation and 8.9 ± 1.3 pg/ml
following TRAIL-stimulation (n = 8/group, p = 0.66 when
compared to non-stimulated cell cultures). After co-
stimulation with TRAIL and LPS, the concentration of
OPG was determined as 7.5 ± 0.8 pg/ml (n = 8/group, p
= 0.25 when compared to TRAIL-stimulated cell cul-
tures, Fig. 4b).
However, TRAIL stimulation significantly decreased
the expression of DR4 whereas the expression of DR5
was increased albeit not to a significant degree (DR4:
1908 ± 296.6 for non-stimulated cell cultures versus
722.4 ± 86.0 for TRAIL-stimulated cell cultures, n = 6, p
= 0.0009; DR5: 866.2 ± 77.6 versus 1018 ± 22.0, p = 0.08).
In contrast, the expression of the decoy receptors DcR1
and DcR2 was increased in TRAIL-stimulated BxPC-3
cell cultures. The mean fluorescence intensity for DcR1
was 783.9 ± 46.7 for non-stimulated cultures of BxPC-3
and TRAIL-treatment significantly increased the ex-
pression of DcR1 reaching a mean fluorescence inten-
sity of 1083.0 ± 52.7 (n = 7, p = 0.0009). Regarding the
expression of DcR2 in BxPC-3 cell cultures, the mean
fluorescence intensity was 287.4 ± 24.5. This was sig-
nificantly increased following TRAIL-stimulation to a
mean fluorescence intensity of 522.3 ± 40.9 (n = 8, p =
0.0002, Fig. 4a).
Co-stimulation with TRAIL and LPS significantly fur-
ther decreased the expression of DR4 and further in-
creased the expression of DcR2 by BxPC-3 cell cultures:
The expression of DR4 by BxPC-3 cell cultures de-
creased from 722.4 ± 86.0 in TRAIL-stimulated cell cul-
tures to 440.0 ± 81.6 in cell cultures co-stimulated with
LPS and TRAIL (n = 6, p = 0.03, Fig. 4a).
Regarding the expression of DcR2 by BxPC-3 cell
cultures, the mean fluorescence raised from 522.3 ±
40.9 in TRAIL-stimulated cell cultures to 631.8 ±
69.0 following co-stimulation with TRAIL and LPS
(n = 8, p = 0.1). However, this effect did not reach
significance.
Fig. 3 Co-stimulation of COLO357 cultures with LPS and TRAIL increased OPG-levels. Cultures of COLO357 were stimulated with 300 ng/ml TRAIL,
1 μg/ml LPS and 300 ng/ml TRAIL + 1 μg/ml LPS for 24 h. Non-stimulated cell cultures served as controls. The concentration of OPG within the
supernatants of respective cell cultures was measured by ELISA. The expression of the TRAIL-receptors 1–4 was determined via FACS analysis. a
The expression of respective TRAIL-receptors was determined by FACS analysis. Data are expressed as mean fluorescence intensity. N = 5/group.
b Concentrations of OPG within the supernatants of COLO357 cultures are depicted. Whereas TRAIL-stimulated cultures displayed a trend toward
decreased OPG-levels, co-stimulation with LPS and TRAIL increased OPG-levels when compared to non-stimulated controls. N = 6/group. Means
and standard errors of the means are shown. **) p < 0.01
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Co-stimulation with LPS and TRAIL did not signifi-
cantly influence the expression of neither DR5 nor DcR1
when compared to TRAIL-stimulated cell cultures.
Regarding the expression of DR5 by BxPC-3 cells, the
mean fluorescence intensity was 1017.5 + − 22.0 in
TRAIL-stimulated cell cultures. In co-stimulated cell
cultures the mean fluorescence intensity was 861.4 ±
112.3 (p = 0.2, n = 8). Regarding the expression of
DcR1, the mean fluorescence intensity was 1083.43 ±
52.7 (n = 7) in TRAIL-stimulated cells and 1001.0 ±
75.7 in co-stimulated cell cultures of BxPC-3 (n = 8)
(p = 0.4; Fig. 4a).
Pancreatic cancer cell lines expressed TLR4 and TRAIL-
stimulation decreased the expression of TLR4
As TLR4 is the receptor for LPS, we investigated the
expression of this receptor in pancreatic cancer cell
lines. As shown by RT-PCR, all of the investigated
pancreatic cancer cell lines expressed TLR4. Yet,
TRAIL-stimulation decreased the expression of TLR4 in
all investigated cell lines: TRAIL-stimulation of PANC-1
cell cultures led to a 3.2-fold decrease in the expression
of TLR4 (Fig. 5a). In BxPC-3 cells, TRAIL-stimulation
decreased the TLR4 expression 4.4-fold (Fig. 5b). Co-
stimulation with LPS and TRAIL further decreased the
expression of TLR4 resulting in a 35.3-fold decrease
when compared to non-stimulated cultures of BxPC-3
cells (Fig. 5b). In COLO 357 cells, TRAIL-stimulation
induced a 31.1-fold decrease in the expression of
TLR4. Co-stimulation with TRAIL and LPS further
decreased TLR4 reaching a 933.3 fold decrease when
compared to non-stimulated COLO 357 cell cultures
(n = 5/group, Fig. 5c).
Discussion
In this study, it could be shown that LPS-stimulation
inhibited TRAIL-induced apoptosis in pancreatic cancer
cell lines by modulating the expression patterns of
respective TRAIL-receptors.
TRAIL is a member of the TNF superfamily and was
initially thought to selectively induce apoptosis in cancer
cells [28]. However, more recently it has been discovered
that TRAIL also exerts a negative impact on immune
cells [27, 29, 30] demonstrating promotion of tumour
growth in a murine model of pancreatic cancer [31].
Fig. 4 Co-stimulation with TRAIL and LPS significantly affected the impact of TRAIL on TRAIL-receptor-expression in BxPC-3 cells. Cultures of
BxPC-3 were stimulated with 300 ng/ml TRAIL, 1 μg/ml LPS and 300 ng/ml TRAIL + 1 μg/ml LPS for 24 h. Non-stimulated cell cultures served
as controls. The concentration of OPG within the supernatants of respective cell cultures was measured by ELISA. The expression of the
TRAIL-receptors 1–4 was determined via FACS analysis. a The expression of the TRAIL-receptors 1–4 by BxPC-3 cells was measured by
FACS analysis and is depicted as mean fluorescence intensity. TRAIL-stimulation highly significantly decreased the expression of TRAIL-
receptor 1 (DR4) on BxPC-3 cells. N ≥ 6/group. b Representative histograms are shown. c Concentrations of OPG within the supernatants
of BxPC-3 cultures are depicted. Neither stimulation with TRAIL alone nor co-stimulation with TRAIL and LPS significantly altered the levels
of OPG. N = 8/group. Means and standard errors of the mean are shown. *) p < 0.05; **) p < 0.01; ***) p < 0.001
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To avoid excessive apoptosis induction following
TRAIL-stimulation, many tumour cells developed
several mechanisms to counteract TRAIL-induced apop-
tosis. Several mechanisms can involve different steps of
the TRAIL signalling pathway. Firstly, NF-kB mediated
survival mechanisms have been discovered involving
genes like X-linked inhibitor of apoptosis (XIAP). Sec-
ondly, the expression pattern of different TRAIL-
receptors can contribute to TRAIL-resistance. Whereas
the expression of TRAIL-R1 (DR4) and TRAIL-R2
(DR5) contributes to TRAIL-induced apoptosis [32, 33],
these effects can be counteracted through the binding of
TRAIL to the decoy receptors DcR1, DcR2 and osteo-
protegerin [34]. Variations in the expression of these
receptors will thus influence the impact on TRAIL-
induced apoptosis.
Previously it has been shown that sensitivity to
TRAIL-induced apoptosis may differ between cell lines
of pancreatic cancer cells: PANC-1 has been detected to
be TRAIL-resistant, whereas the cell line BxPC-3 ap-
pears to be TRAIL-sensitive. This effect was contributed
to KRAS mutations in PANC-1 cell lines [22, 35]. This
present study confirmed the finding: COLO 357 dis-
played a high sensitivity to TRAIL-induced apoptosis,
BxPC-3 displayed an intermediate sensitivity and PANC-
1 cells were resistant to TRAIL-induced apoptosis.
Previous results could confirme the expression of the
TRAIL-receptors DR4, DR5, DcR1, DcR2 and osteopro-
tegerin showing that these receptors were expressed by
all investigated cell lines [22]. Additionally, it could be
shown that all investigated cell lines secreted osteopro-
tegerin (OPG). However, there were significant differ-
ences between the investigated cell lines regarding the
regulation of the expression of TRAIL-receptors follow-
ing TRAIL-stimulation. In the TRAIL-resistant cell line
PANC-1, TRAIL-stimulation significantly decreased the
expression of the death receptors DR4 and DR5 whereas
the secretion of osteoprotegerin was significantly in-
creased. The levels of OPG in PANC-1 cell cultures were
highest, confirming reports linking K-RAS mutations in
pancreatic cancer cells with levels of osteoprotegerin
[36]. Remarkably, in the present study TRAIL-
stimulation increased OPG-levels thereby decreasing the
expression of death receptors. Levels of OPG were
Fig. 5 TRAIL-stimulation decreased the mRNA-levels of TLR4. Cultures of PANC-1 (a), BxPC-3 (b) and COLO357 (c) were stimulated with 300 ng/ml
TRAIL and 300 ng/ml TRAIL + 1 μg/ml LPS for 24 h. Non-stimulated cell cultures served as controls. TLR4 mRNA levels were measured by quantitative
realtime-PCR. Data were normalized to mRNA expression of a housekeeping gene, GAPDH, and shown as fold change compared to untreated cells.
Means and standard errors of the mean are shown. *) p < 0.05; **) p < 0.01
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lowest in the KRAS wild type cell line BxPC-3. TRAIL-
stimulation had no influence on OPG secretion. How-
ever, the expression of DR4 was decreased following
TRAIL-stimulation and the expression of the decoy
receptors DcR1 and DcR2 was increased resulting in an
intermediate resistant phenotype. In contrast, the cell
line COLO 357 displayed a high sensitivity to TRAIL-
mediated apoptosis. Following TRAIL-treatment the
levels of OPG were decreased whereas the expression
pattern of the receptors DR4, DR5, DcR1 and DcR2 did
not alter.
Toll-like receptors are a major class of pattern recog-
nition receptors which recognize highly conserved mi-
crobial structures called pathogen-associated molecular
patterns (PAMPs) allowing the immune system to iden-
tify a variety of pathogens [7]. Therefore, TLRs are able
to detect pathogens and subsequently initiate an imme-
diate immune response.
TLR4 which binds LPS was the first Toll-like receptor
to be identified. Therefore, it plays an important role in
innate immunity. Thus, the activation of TLR4 by bac-
terial LPS mounts a pro-inflammatory reaction yielding
in the elimination of the pathogen [37].
Apart from their expression on immune cells, Toll-like
receptors have been identified in many other cell types
including endothelial cells, myocytes and thyreocytes.
Additionally, TLR expression has been found on pancre-
atic beta-cells, alpha-cells and even ductal cells [38].
In pancreatic ductal adenocarcinoma an increased
expression of TLR4 has been detected compared to adja-
cent normal tissue [39]. In this study, we have confirmed
and expanded these investigations showing that all in-
vestigated pancreatic cancer cell lines expressed Toll-like
receptor 4.
TLR4 appears to act as a double-edged sword as it has
been linked to both cancer inhibition and growth [40].
Whereas TLR4−/− mice showed decreased tumour
growth in a murine model of pancreatic cancer, inhib-
ition of MyD88 accelerated tumour development [41] as
well as an increased TLR4 expression correlated with
tumour size, lymph node involvement, venous invasion
and pathological stage [39]. Most reports regarding pan-
creatic cancer and TLRs however focus on interactions
of respective ligands with immune cells of the tumour’s
microenvironment. With lung cancer cells it has been
shown that TLR4-signalling promoted resistance to-
wards TRAIL-induced apoptosis and that this effect
could be induced by LPS-stimulation [26]. For the pan-
creatic cancer cell lines PANC-1 and AsPC-1 it has been
demonstrated that LPS-stimulation increased the
invasive ability of respective cell lines through NFkB
signalling [5].
This study showed an effect of LPS-signalling on the
sensitivity to TRAIL-induced apoptosis in pancreatic
cancer cell lines. This effect has been detected in all in-
vestigated TRAIL-sensitive cell lines and showed a
strong reduction of TRAIL-induced apoptosis. In BxPC-
3 cells, this effect was accompanied by an increase in the
expression of DcR1 and a decrease of DR4-expression
whereas the expression of DR5 and DcR2 remained un-
changed when compared to TRAIL-stimulation. There
were no changes detected in the secretion of OPG. In
contrast, in COLO 357 cells the expression of the
TRAIL-receptors was not changed comparing TRAIL-
stimulated cell cultures with cell cultures stimulated
with TRAIL and LPS. However, there was a significant
increase in the level of osteoprotegerin contributing to
TRAIL-resistance following co-stimulation [36].
Despite this fundamental role of LPS on TRAIL-
function, the significance of TLR4 in this context has yet
to be analysed. All cell lines expressed TLR4 but its level
of expression was significantly reduced by TRAIL-
stimulation. Therefore, only small numbers of functional
TLR4s are required for LPS-mediated TRAIL-inhibition.
In summary, TLR4 was expressed on all analysed pan-
creatic cancer cell lines. LPS-stimulation decreased
TRAIL-induced apoptosis. The decreased resistance to
TRAIL-induced apoptosis was accompanied by alter-
ation in the patterns expression of TRAIL-receptors. Fu-
ture TRAIL-therapeutic strategies must be aimed at
restoring TRAIL sensitivity by increasing functional
TRAIL-receptors, blocking decoy receptors and other
TRAIL-binding proteins as well as by counter-acting the
inflammatory micro-milieu in pancreatic cancer. The
role of LPS and TLR4 has to be further elucidated in
future studies.
Conclusions
In this study, it has been shown that TRAIL-resistance in
pancreatic cancer cells can be mediated by the inflamma-
tory molecule LPS as well as by different expression pat-
terns of functional and non-functional TRAIL-receptors.
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